Researchers from the Center for Nuclear Energy in Agriculture at the University of São Paulo (CENA-USP) have identified multiple classes…
Read More
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders
OrsoBio, a specialized biotechnology company strategically focused on addressing obesity and its myriad related metabolic dysfunctions, is charting a course…
Read More
Novo Nordisk’s New Weight Loss Treatment CagriSema Shows Inferiority to Lilly’s Tirzepatide in Head-to-Head Trial
Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its eagerly anticipated weight loss treatment,…
Read More
Dulaglutide Shows Promise in Stabilizing Coronary Plaques, Revolutionizing Cardiovascular Protection Beyond Diabetes Management
The intricate relationship between Type 2 diabetes (T2D) and cardiovascular health has long been a focal point of medical research.…
Read More
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders
OrsoBio, a specialized biotechnology firm dedicated to pioneering treatments for obesity and its associated metabolic disorders, is strategically charting a…
Read More
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders and pioneering a new frontier in obesity therapeutics
OrsoBio, a dynamic biotech enterprise dedicated to advancing novel therapies for obesity and a spectrum of obesity-related metabolic disorders, is…
Read MoreYOU MAY HAVE MISSED
